Table 5.
Views on Oversight of Gene Editing Research
| Who should be included in the decision-making process about the oversight of gene-editing research? (Select all that apply) | Who is best positioned to oversee how gene editing research should be conducted? (Select one) | |
|---|---|---|
| Industry representatives | 35% | 0% |
| International bodies (e.g., World Health Organization) | 76% | 15% |
| Lay people | 48% | 1% |
| National government offices (e.g., National Institutes of Health, Food and Drug Administration) | 95% | 48% |
| Patients and patient advocates | 76% | 1% |
| Religious officials | 22% | 0% |
| Scientists | 96% | 28% |
| University offices (e.g., Institutional Review Boards, Institutional Animal Care and Use Committees) | 66% | 6% |
| Other | 6% | 2% |